Open an account

Pharvaris NV

PHVS · NASDAQ

$31.41+$0.73 (+2.38%)TodayMarket closed ·
Prev close $30.68

About PHVS

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 129 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Employees
129
Headquarters
Leiden, Zuid-Holland
Listed
Feb 5, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
pharvaris.com

PHVS key statistics

Market cap
2.19B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
685.82K
Volume
621.75K
Open price
$31.57
High today
$32.12
Low today
$30.25
52 Week high
$43.25
52 Week low
$21.02

Pharvaris NV (PHVS) at a glance

Pharvaris NV (PHVS) last traded at $31.41, with a market cap of 2.19B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $30.25 and $32.12. The current price is 3.8% above the day's low and 2.2% below its high.

Volume so far is 621.75K shares, in line with the average of 685.82K shares a day.

Over the past year Pharvaris NV has ranged from $21.02 to $43.25, and now sits 47% of the way up that range.

Pharvaris NV met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.70 per share against an estimate of -$0.6651.

The average analyst price target is $59.67, 90.0% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 13 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 16 analystsAvg $59.67
Low
$42.42
Now
$31.41
High
$82.95

PHVS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 14.7% on average.

  1. Q3 FY24: reported -$0.77 per share against an estimate of -$0.6228
  2. Q4 FY24: reported -$0.64 per share against an estimate of -$0.7355
  3. Q1 FY25: reported -$0.85 per share against an estimate of -$0.7785
  4. Q2 FY25: reported -$0.83 per share against an estimate of -$0.7862
  5. Q3 FY25: reported -$0.597 per share against an estimate of -$0.6806
  6. Q4 FY25: reported -$0.72 per share against an estimate of -$0.6333
  7. Q1 FY26: reported -$0.59 per share against an estimate of -$0.7262
  8. Q2 FY26: reported -$0.70 per share against an estimate of -$0.6651

PHVS news

  • Vandana Singh

    Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

  • Avi Kapoor

    Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

  • Vandana Singh

    Why Is Pharvaris Stock Soaring Tuesday?

  • Press releaseGlobe Newswire

    Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

  • Press releaseGlobe Newswire

    Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

  • Press releaseGlobe Newswire

    Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

  • Press releaseGlobe Newswire

    Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.